Literature DB >> 27900099

Effect of cytostatic proline rich polypeptide-1 on tumor suppressors of inflammation pathway signaling in chondrosarcoma.

Karina Galoian1, Shihua Luo1, Amir Qureshi1, Parthik Patel1, Rachel Price1, Ashlyn S Morse1, Gor Chailyan2, Silva Abrahamyan2, H T Temple3.   

Abstract

Cytokines produced in the tumour microenvironment exert an important role in cancer pathogenesis and in the inhibition of disease progression. Cancer of the cartilage is termed metastatic chondrosarcoma; however, the signaling events resulting in mesenchymal cell transformation to sarcoma have yet to be fully elucidated. The present study aimed to characterize the cytokine expression profile in the human JJ012 chondrosarcoma cell line, as well as the effect of cytostatic proline-rich polypeptide-1 (PRP-1). Western blot experiments demonstrated that the levels of suppressor of cytokine signaling 3 (SOCS3) were upregulated in chondrocytes compared with chondrosarcoma cells. Addition of PRP-1 restored the expression of the tumor suppressors, SOCS3 and ten-eleven-translocation methylcytosine dioxygenase 1 and 2 (TET1/2), in a dose-responsive manner. It is known that methylation of histone H3K9 was eliminated from the promoters of the inflammation-associated genes. PRP-1 inhibited H3K9 demethylase activity with an IC50 (concentration required to give half-maximal inhibition) value of 3.72 µg/ml in the chondrosarcoma cell line. Data obtained from ELISA experiments indicated that the expression of interleukin-6 (IL-6) in chondrosarcoma cells was 86-fold lower compared with that in C28 chondrocytes. In the present study, a 53-fold downregulation of IL-6 expression in co-culture of chondrosarcoma cells and C28 chondrocytes was identified as well. Downregulation of IL-6 expression has been documented in numerous other tumor types, although the reasons for this have not been fully established. In chondrosarcoma, IL-6 manifests itself as an anti-inflammatory agent and, possibly, as an anti-tumorigenic factor. To explore protein-DNA interactions leading to such differences, a gel-shift chemiluminescent assay was performed. Gel shifts were observed for chondrosarcoma and chondrocytes in the lanes that contained nuclear cell extract and oligo-IL-6 DNA. Notably, the DNA-protein complexes in C28 chondrocytes were markedly larger compared with those in chondrosarcoma cells. The mechanisms that underpin such differences, and characterization of the interacting proteins, remain to be fully elucidated.

Entities:  

Keywords:  chondrosarcoma; inflammation; interleukin-6; proline-rich polypeptide-1; suppressor of cytokine signaling 3

Year:  2016        PMID: 27900099      PMCID: PMC5103888          DOI: 10.3892/mco.2016.1010

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  45 in total

1.  Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis.

Authors:  Daewoong Jo; Danya Liu; Shan Yao; Robert D Collins; Jacek Hawiger
Journal:  Nat Med       Date:  2005-07-10       Impact factor: 53.440

2.  mTORC1 inhibition and ECM-cell adhesion-independent drug resistance via PI3K-AKT and PI3K-RAS-MAPK feedback loops.

Authors:  Karina Galoian; H T Temple; Armen Galoyan
Journal:  Tumour Biol       Date:  2012-01-14

3.  Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6.

Authors:  Qian Zhang; Kai Zhao; Qicong Shen; Yanmei Han; Yan Gu; Xia Li; Dezhi Zhao; Yiqi Liu; Chunmei Wang; Xiang Zhang; Xiaoping Su; Juan Liu; Wei Ge; Ross L Levine; Nan Li; Xuetao Cao
Journal:  Nature       Date:  2015-08-19       Impact factor: 49.962

4.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

5.  Epigenetic regulation of embryonic stem cell marker miR302C in human chondrosarcoma as determinant of antiproliferative activity of proline-rich polypeptide 1.

Authors:  Karina Galoian; Amir Qureshi; Gianluca D'Ippolito; Paul C Schiller; Marco Molinari; Andrea L Johnstone; Shaun P Brothers; Ana C Paz; H T Temple
Journal:  Int J Oncol       Date:  2015-06-18       Impact factor: 5.650

6.  Restored expression levels of TET1 decrease the proliferation and migration of renal carcinoma cells.

Authors:  Min Fan; Xiaozhou He; Xianlin Xu
Journal:  Mol Med Rep       Date:  2015-07-08       Impact factor: 2.952

Review 7.  Chronic inflammation and cytokines in the tumor microenvironment.

Authors:  Glauben Landskron; Marjorie De la Fuente; Peti Thuwajit; Chanitra Thuwajit; Marcela A Hermoso
Journal:  J Immunol Res       Date:  2014-05-13       Impact factor: 4.818

Review 8.  Cancer development, progression, and therapy: an epigenetic overview.

Authors:  Sibaji Sarkar; Garrick Horn; Kimberly Moulton; Anuja Oza; Shannon Byler; Shannon Kokolus; McKenna Longacre
Journal:  Int J Mol Sci       Date:  2013-10-21       Impact factor: 5.923

9.  Antitumor activity of recombinant interleukin 6 in mice.

Authors:  J J Mulé; J K McIntosh; D M Jablons; S A Rosenberg
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

10.  Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.

Authors:  Johnny Suijker; Jan Oosting; Annemarie Koornneef; Eduard A Struys; Gajja S Salomons; Frank G Schaap; Cathelijn J F Waaijer; Pauline M Wijers-Koster; Inge H Briaire-de Bruijn; Lizette Haazen; Scott M Riester; Amel Dudakovic; Erik Danen; Anne-Marie Cleton-Jansen; Andre J van Wijnen; Judith V M G Bovée
Journal:  Oncotarget       Date:  2015-05-20
View more
  5 in total

1.  Analysis of IL6-protein complexes in chondrosarcoma.

Authors:  Karina Galoian; Shihua Luo; Parthik Patel
Journal:  Biomed Rep       Date:  2017-11-10

2.  Toll like receptors TLR1/2, TLR6 and MUC5B as binding interaction partners with cytostatic proline rich polypeptide 1 in human chondrosarcoma.

Authors:  Karina Galoian; Silva Abrahamyan; Gor Chailyan; Amir Qureshi; Parthik Patel; Gil Metser; Alexandra Moran; Inesa Sahakyan; Narine Tumasyan; Albert Lee; Tigran Davtyan; Samvel Chailyan; Armen Galoyan
Journal:  Int J Oncol       Date:  2017-11-09       Impact factor: 5.650

3.  Cancer stem cells as a therapeutic target in 3D tumor models of human chondrosarcoma: An encouraging future for proline rich polypeptide‑1.

Authors:  Caroline J Granger; Aaron K Hoyt; Alexandra Moran; Beatrice Becker; Anil Sedani; Shannon Saigh; Sheila A Conway; Jeffrey Brown; Karina Galoian
Journal:  Mol Med Rep       Date:  2020-09-02       Impact factor: 2.952

4.  Morpho‑functional study of the hypothalamic proline‑rich polypeptide apoptotic activity against mouse Ehrlich ascites carcinoma.

Authors:  S Abrahamyan; I Sahakyan; N Tumasyan; N Kocharyan; A Simonyan; R Aroutiounian; G Chailyan; S Chailyan; T Davtyan; K Galoian
Journal:  Oncol Rep       Date:  2020-05-04       Impact factor: 3.906

5.  In vitro study on aspects of molecular mechanisms underlying invasive aspergillosis caused by gliotoxin and fumagillin, alone and in combination.

Authors:  Loganathan Gayathri; Mohammad A Akbarsha; Kandasamy Ruckmani
Journal:  Sci Rep       Date:  2020-09-02       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.